Brean Murray Initiates Coverage on Ariad Pharmaceuticals (ARIA) with a Hold; Strong Fundamentals, Cautious on Phase 3 Trial
Tweet Send to a Friend
Brean Murray initiates coverage on Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA) with a Hold rating.
Brean analyst says, "Ariad is a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says, "Ariad is a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
